Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
NCT ID: NCT03662204
Last Updated: 2022-09-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
5133 participants
OBSERVATIONAL
2018-08-23
2022-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069
Biomarker Identification for Bladder Cancer Patients
NCT02053662
Prospective Study to Assess a Diagnostic Aid for Cancer
NCT07046260
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
NCT03727009
Healthy Human Control Blood Collection for Validation of Biomarker Assay
NCT02302885
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Breast
Subjects with clinically confirmed breast cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
Lung
Subjects with clinically confirmed lung cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
Colorectal
Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
Prostate
Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
Bladder
Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
Uterine
Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
Kidney & Renal Pelvis
Subjects with clinically confirmed or suspicion of kidney or renal pelvis cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
Pancreatic
Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
Liver
Subjects with clinically confirmed liver cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
Stomach
Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
Ovarian
Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
Esophageal
Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject has an untreated primary malignancy of breast, lung, colorectal, prostate, bladder, uterine, kidney/renal pelvis, pancreatic, liver, stomach, ovarian or esophageal cancer.
OR
Subject has suspicion of a primary malignancy of pancreatic, bladder, kidney/renal pelvis, or ovarian cancer based on imaging.
3. Subject understands the study procedures and is able to provide informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.
Exclusion Criteria
1. Any previous cancer diagnosis within the past 5 years (with the exceptions of basal cell or squamous cell skin cancers); OR
2. Recurrence of the same primary cancer within any timeframe; OR
3. Concurrent diagnosis of multiple primary cancers
2. Chemotherapy and/or radiation therapy within 5 years prior to enrollment/sample collection.
3. Any treatment for the primary malignancy or sites of metastases. Subject may not have started neo-adjuvant chemotherapy, neo-adjuvant radiation therapy, immunotherapy or other treatment and/or surgery prior to blood sample collection.
4. Less than 3 days between fine needle aspiration (FNA) of target pathology and blood collection.
5. Less than 7 days between biopsy (other than FNA) of target pathology and blood collection.
6. IV contrast (e.g. CT and MRI) within 1 day \[or 24 hours\] of blood collection.
7. Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Exact Sciences Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Hospital
Phoenix, Arizona, United States
Scottsdale Medical Imaging Research
Scottsdale, Arizona, United States
Arizona Clinical Research Center, Inc.
Tucson, Arizona, United States
Urological Associates of Southern Arizona, PC
Tucson, Arizona, United States
Mercy Research-Fort Smith
Fort Smith, Arkansas, United States
Genesis Cancer Center
Hot Springs, Arkansas, United States
NEA Fowler Family Center for Cancer Care
Jonesboro, Arkansas, United States
CARTI Cancer Center
Little Rock, Arkansas, United States
John Muir Clinical Research
Concord, California, United States
Marin Cancer Care
Greenbrae, California, United States
Alliance Research Centers
Laguna Hills, California, United States
Office of John Homan, MD
Newport Beach, California, United States
North County Oncology
Oceanside, California, United States
UCI Department of Urology
Orange, California, United States
Sharp Memorial Hospital
San Diego, California, United States
St. Joseph Heritage Healthcare
Santa Rosa, California, United States
Adventist Health - Saint Helena Hospital
St. Helena, California, United States
Innovative Clinical Research Institute
Whittier, California, United States
RMR VA Medical Center
Aurora, Colorado, United States
The Urology Center of Colorado
Denver, Colorado, United States
Middlesex Hospital
Middletown, Connecticut, United States
Easter Ct Hematology and Oncology
Norwich, Connecticut, United States
Stamford Hospital
Stamford, Connecticut, United States
Southeast Florida Hematology-Oncology Group, PA
Fort Lauderdale, Florida, United States
CSNF - Central Business Office
Jacksonville, Florida, United States
Jupiter Medical Center
Jupiter, Florida, United States
Mount Sinai Medical Center
Miami Beach, Florida, United States
Mid Florida Hematology and Oncology Center
Orange City, Florida, United States
Sarasota Memorial Hospital
Sarasota, Florida, United States
University Cancer & Blood Center, LLC
Athens, Georgia, United States
Piedmont Cancer Institute, PC
Atlanta, Georgia, United States
Candler Hospital
Savannah, Georgia, United States
Lewis Hall Singletary Oncology Center
Thomasville, Georgia, United States
John H. Stroger, Jr. Hospital of Cook County
Chicago, Illinois, United States
PMG Research of DuPage Medical Group
Downers Grove, Illinois, United States
Presence Cancer Care / JOHA
Joliet, Illinois, United States
Illinois CancerCare, P.C.
Peoria, Illinois, United States
Orchard Healthcare Reasearch Inc
Skokie, Illinois, United States
SIU School of Medicine
Springfield, Illinois, United States
Investigative Clinical Research of Indiana, LLC
Indianapolis, Indiana, United States
PMG Research of McFarland Clinic
Ames, Iowa, United States
Des Moines Oncology Research Associate
Des Moines, Iowa, United States
Oncology Fort Thomas St. Elizabeth's Edgewood Cancer Care Research
Edgewood, Kentucky, United States
Baptist Health-Lexington
Lexington, Kentucky, United States
Norton Cancer Institute-Pavilion
Louisville, Kentucky, United States
Baptist Health
Louisville, Kentucky, United States
Baptist Health- Paducah
Paducah, Kentucky, United States
Greater Baltimore Medical Center
Baltimore, Maryland, United States
Holy Cross Hospital Resource Center Department of Cancer Research
Silver Spring, Maryland, United States
Beverly Hospital, Oncology
Beverly, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Lowell General Hospital
Lowell, Massachusetts, United States
Cancer and Hematology Centers of Western Michigan, PC
Grand Rapids, Michigan, United States
Cancer Research Consortium of West Michigan (CRCWM)
Grand Rapids, Michigan, United States
Ascension Providence Hospitals
Southfield, Michigan, United States
Metro-Minnesota Community Oncology Research Consortium (MMCORC)
Saint Louis Park, Minnesota, United States
Park Nicollet Institute - Oncology Research
Saint Louis Park, Minnesota, United States
St. Dominic's Gynecologic Oncology
Jackson, Mississippi, United States
North Mississippi Medical Center Hematology and Oncology
Tupelo, Mississippi, United States
Mercy Cancer Center
Joplin, Missouri, United States
Mercy Cancer and Hematology Clinic
Springfield, Missouri, United States
Missouri Baptist Medical Center
St Louis, Missouri, United States
Mercy Hospital
St Louis, Missouri, United States
Nebraska Hematology-Oncology -- Lincoln
Lincoln, Nebraska, United States
Somnos Laboratories, Inc.
Lincoln, Nebraska, United States
Cancer Care Specialists
Reno, Nevada, United States
The Minniti Center for Hematology and Oncology
Mickleton, New Jersey, United States
Riverview Medical Center
Red Bank, New Jersey, United States
Albany Medical College
Albany, New York, United States
Brooklyn Urology Research Group
Brooklyn, New York, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Hematology Oncology Associates of Central New York
East Syracuse, New York, United States
Premier Medical Group of the Hudson Valley PC
Poughkeepsie, New York, United States
Premier Medical Group of the Hudson Valley, PC Research Department - Gastroenterology Division
Poughkeepsie, New York, United States
Richmond University Medical Center
Staten Island, New York, United States
Stony Brook Cancer Center
Stony Brook, New York, United States
Associated Medical Professionals
Syracuse, New York, United States
Cone Health Cancer Center
Greensboro, North Carolina, United States
PMG Research of Hickory, LLC
Hickory, North Carolina, United States
FirstHealth Moore Regional Hospital
Pinehurst, North Carolina, United States
PMG Research of Rocky Mount
Rocky Mount, North Carolina, United States
PMG Research of Piedmont
Statesville, North Carolina, United States
Marion L. Shepard Cancer Center
Washington, North Carolina, United States
Zimmer Cancer Center
Wilmington, North Carolina, United States
Hematology & Oncology Associates, Inc.
Canton, Ohio, United States
Tri-County Hematology & Oncology Associates, Inc.
Massillon, Ohio, United States
Cancer Centers of Southwest Oklahoma
Lawton, Oklahoma, United States
Genie Jackson Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Mercy Oncology Research
Oklahoma City, Oklahoma, United States
St. Luke's University Health Network
Bethlehem, Pennsylvania, United States
Women & Infants Hospital
Providence, Rhode Island, United States
Charleston Cancer Center
Charleston, South Carolina, United States
McLeod Center for Cancer Treatment and Research
Florence, South Carolina, United States
Saint Francis Cancer Center Research Department
Greenville, South Carolina, United States
Lowcountry Urology/PMG Research of Charleston, LLC
North Charleston, South Carolina, United States
Spartanburg Medical Center: Gibbs Cancer Center & Research Institute
Spartanburg, South Carolina, United States
Lexington Medical Center
West Columbia, South Carolina, United States
RH Clinical Research
Rapid City, South Dakota, United States
PMG Research of Bristol, LLC
Bristol, Tennessee, United States
The Jackson Clinic
Jackson, Tennessee, United States
Christus Spohn Cancer Center
Corpus Christi, Texas, United States
University of Texas Health Science Center
Houston, Texas, United States
Sun Research Institute
San Antonio, Texas, United States
San Antonio Military Medical Center
San Antonio, Texas, United States
Cancer Treatment Center
Texarkana, Texas, United States
Renovatio Clinical
The Woodlands, Texas, United States
Community Cancer Trials of Utah
Ogden, Utah, United States
Utah Cancer Specialists
Salt Lake City, Utah, United States
Virginia Cancer Institute
Richmond, Virginia, United States
Urology of Virginia, PLLC
Virginia Beach, Virginia, United States
Seattle Urology Research Center
Burien, Washington, United States
MultiCare Regional Cancer Center
Tacoma, Washington, United States
CAMC Clinical Trials Center
Charleston, West Virginia, United States
Mon Health Medical Center
Morgantown, West Virginia, United States
West Virginia University Cancer Institute
Morgantown, West Virginia, United States
HSHS St. Vincent Hospital
Green Bay, Wisconsin, United States
Michael Berry Building-Oncology
Janesville, Wisconsin, United States
UW Carbone Cancer Center
Madison, Wisconsin, United States
ProHealth Care Research Institute
Waukesha, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.